These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28794366)

  • 1. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
    Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
    Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

  • 6. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
    CsToth I; Meert AP; Sculier JP; Berghmans T
    Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
    Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
    Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.
    Miyamoto S; Ikushima S; Ono R; Awano N; Kondo K; Furuhata Y; Fukumoto K; Kumasaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):170-3. PubMed ID: 26613679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.
    Yoneshima Y; Okamoto I; Arimura-Omori M; Kimura S; Hidaka-Fujimoto N; Iwama E; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Apr; 33(2):510-2. PubMed ID: 25433426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
    Chino H; Sekine A; Kitamura H; Kato T; Ogura T
    Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
    Koizumi T; Fukushima T; Tatai T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S
    Lung Cancer; 2015 Apr; 88(1):112-3. PubMed ID: 25678258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
    Halpenny DF; McEvoy S; Li A; Hayan S; Capanu M; Zheng J; Riely G; Ginsberg MS
    Lung Cancer; 2017 Apr; 106():33-36. PubMed ID: 28285691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
    Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
    Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
    Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.
    Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK
    Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
    Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.